The discovery of immune checkpoint proteins such as PD-1/PDL-1 and CTLA-4 represents a
significant breakthrough in the field of cancer immunotherapy. Therefore, humanized …

Background The role of tumor mutational burden (TMB) is still debated for selecting
advanced non-oncogene addicted non-small-cell lung cancer (NSCLC) patients who might …

Lung carcinogenesis is a complex and stepwise process involving accumulation of genetic
mutations in signaling and oncogenic pathways via interactions with environmental factors …

Inherited lung cancer risk, particularly in nonsmokers, is poorly understood. Genomic and
ancestry analysis of 1,153 lung cancers from Latin America revealed striking associations …

Immunotherapy is a promising approach to treating various types of cancers, including
hepatocellular carcinoma (HCC). While single immunotherapy drugs show limited …

The past decade has witnessed a revolution in cancer treatment by the shift from
conventional drugs (chemotherapies) towards targeted molecular therapies and immune …

Background Immunotherapy with immune checkpoint inhibitors (ICIs) is highly effective in
microsatellite instability–high (MSI‐H) metastatic colorectal cancer (mCRC); however …

Non-small cell lung cancers (NSCLCs) harboring KEAP1 mutations are often resistant to
immunotherapy. Here, we show that KEAP1 targets EMSY for ubiquitin-mediated …

Non-small cell lung cancer (NSCLC) is one of the most threatening malignancies to human
health and life. In most cases, patients with NSCLC are already at an advanced stage when …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy worldwide
and a leading cause of death worldwide. Its incidence continues to increase in the US due to …